Moomoo AI 已提取核心訊息
Allarity Therapeutics, Inc., a biopharmaceutical company, has reported the termination of employment of its Chief Medical Officer, Marie Foegh, M.D., as disclosed in a Form 8-K filing with the United States Securities and Exchange Commission. The termination was effective as of February 29, 2024. The company, listed on the Nasdaq Stock Market under the trading symbol ALLR, is classified as an emerging growth company. The report was officially signed by an authorized representative of Allarity Therapeutics, Inc. on March 4, 2024.
Allarity Therapeutics, Inc., a biopharmaceutical company, has reported the termination of employment of its Chief Medical Officer, Marie Foegh, M.D., as disclosed in a Form 8-K filing with the United States Securities and Exchange Commission. The termination was effective as of February 29, 2024. The company, listed on the Nasdaq Stock Market under the trading symbol ALLR, is classified as an emerging growth company. The report was officially signed by an authorized representative of Allarity Therapeutics, Inc. on March 4, 2024.
生物製藥公司Allarity Therapeutics, Inc. 報告稱，向美國證券交易委員會提交的8-K表格中披露了其首席醫療官Marie Foegh醫學博士的終止聘用。終止自2024年2月29日起生效。該公司在納斯達克股票市場上市，交易代碼爲ALLR，被列爲新興成長型公司。該報告由Allarity Therapeutics, Inc.的授權代表於2024年3月4日正式簽署。
生物製藥公司Allarity Therapeutics, Inc. 報告稱，向美國證券交易委員會提交的8-K表格中披露了其首席醫療官Marie Foegh醫學博士的終止聘用。終止自2024年2月29日起生效。該公司在納斯達克股票市場上市，交易代碼爲ALLR，被列爲新興成長型公司。該報告由Allarity Therapeutics, Inc.的授權代表於2024年3月4日正式簽署。
有用
沒用